Accro Bioscience’s AC-101 added to China’s rare-disease drug development pilot
AI Summary- Accro Bioscience added AC-101 tablets to China’s rare-disease development pilot program.
- AC-101 received FDA Rare Pediatric Disease designation in June 2026.
- Results from AC-101’s Chinese ulcerative colitis study will be presented at UEG Week 2026.